COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

What’s Next for COVID-19 Vaccines and Variants?

More technologies and treatments are emerging for COVID-19—along with new variants.

Key Elements for Assay Transfer Success

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Cold Comfort for Bio/Pharma

March 02, 2022

Continuous improvements in technologies and services will help cold chain operators meet future industry demand.

Supply Chain Vulnerabilities in a Post-Pandemic World

March 02, 2022

Although the bio/pharma supply chain has vulnerabilities that still need to be addressed, the COVID-19 pandemic has left lasting effects—some of them for the better.

FDA Updates Sotrovimab Emergency Use Authorization

March 01, 2022

FDA has revised the Emergency Use Authorization for sotrovimab.

EMA Recommends Approval of Spikevax for Children Aged 6 to 11

February 28, 2022

EMA has recommended approval of Spikevax for children aged 6 to 11.

EMA Issues Positive Opinion on Pfizer and BioNTech COVID-19 Vaccine Booster in Adolescents 12 Through 17 Years of Age in EU

February 28, 2022

Pfizer and BioNTech receive positive opinion for COVID-19 vaccine booster in adolescents 12 through 17 years of age in the EU.